ConductScience.org, home

Gene · 50484

RRM2B: ribonucleotide reductase regulatory TP53 inducible subunit M2B

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. RRM2B: ribonucleotide reductase regulatory TP53 inducible subunit M2B. Genes, record 50484. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/50484

On this page

Gene

Symbol
RRM2B
HGNC
Name
ribonucleotide reductase regulatory TP53 inducible subunit M2B
HGNC
NCBI Gene ID
50484
NCBI Gene
HGNC ID
HGNC:17296
HGNC
Ensembl
ENSG00000048392
NCBI Gene
Aliases
MTDPS8A, MTDPS8B, P53R2, RCDFRD, p53R2
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q7LG56Ribonucleoside-diphosphate reductase subunit M2 B3513Ensembl, GeneID, HGNC

Source UniProt

Patents24

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1461939Q7LG56Espacenet
EP 4650780 A22025-11-191359Q7LG56Espacenet
EP 4641201 A22025-10-29986Q7LG56Espacenet
JP 2025529142 A2025-09-043786Q7LG56Espacenet
US 12371689 B22025-07-293786Q7LG56Espacenet
JP 2025517969 A2025-06-12986Q7LG56Espacenet
JP 2025517970 A2025-06-121359Q7LG56Espacenet
US 11446398 B22022-09-2073874Q7LG56Espacenet
US 11400116 B22022-08-024116Q7LG56Espacenet
JP 2022524081 A2022-04-27176845Q7LG56Espacenet

1 to 10 of 24

See all 24 patents

Drugs10

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
CLOFARABINECHEMBL1750Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
FLUDARABINE PHOSPHATECHEMBL1096882Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
GALLIUM NITRATECHEMBL1200983Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
GEMCITABINECHEMBL888Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
GEMCITABINE HYDROCHLORIDECHEMBL1637Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
HYDROXYUREACHEMBL467Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
MOTEXAFIN GADOLINIUMCHEMBL3544910Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
TEZACITABINECHEMBL3989496Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
TEZACITABINE ANHYDROUSCHEMBL2105467Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
TRIAPINECHEMBL231616Ribonucleotide reductase inhibitorINHIBITORChEMBL

Trials3,175

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07604766GEMCITABINEPHASE3ClinicalTrials.gov
NCT07603557FLUDARABINE PHOSPHATEPHASE2ClinicalTrials.gov
NCT07602140GEMCITABINEPHASE2ClinicalTrials.gov
NCT07598318GEMCITABINEPHASE2/PHASE3ClinicalTrials.gov
NCT07579195GEMCITABINEPHASE1/PHASE2ClinicalTrials.gov
NCT07575191GEMCITABINEPHASE1/PHASE2ClinicalTrials.gov
NCT07570849GEMCITABINEPHASE2ClinicalTrials.gov
NCT07570823GEMCITABINEPHASE3ClinicalTrials.gov
NCT07570017GEMCITABINEPHASE1ClinicalTrials.gov
NCT07569679GEMCITABINEPHASE2ClinicalTrials.gov

1 to 10 of 3,175

See all 3,175 trials

NIH grants905

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleRRM2B papersNewest fiscal year
P30CA043703Case Comprehensive Cancer Center Support Grant102025
P30CA033572Cancer Center Support Grant82025
ZIAES065078Molecular Characterization Of The Mitochondrial Dna Polymerase82025
P30CA016672Cancer Center Support Grant72025
P30CA016056Roswell Park Cancer Center Support Grant62025
P30CA008748Cancer Center Support Grant52025
ZIAES065080Human Mitochondrial Dna Polymerase With Anti-hiv Nucleotides52025
P30CA010815Consolidated Basic Cancer Research Program42025
R01NS049206Huntington's Disease Repeat Instability and Pathogenesis42025
T32CA009171Training Program in Basic Cancer Research42025

1 to 10 of 905Source NIH's project files

See all 905 nih grants

Papers1,270

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Mechanisms of Hydroxyurea-Mediated DNA Damage Potentiation in Fanconi Anemia Cells.Int J Mol Sci202642589438PubTator, text miningPubMed
RRM2B is associated with low-level viremia during entecavir therapy in pediatric chronic hepatitis B and promotes profibrotic signaling in vitro.Virol J202642436559PubTator, text miningPubMed
Harmane induces apoptosis through RRM2B and suppresses colorectal cancer progression.mSystems202642262096PubTator, text miningPubMed
Multi-omics integration provides biological insight and prioritizes potential drug targets in multiple sclerosis progression.J Neuroinflammation202642231304PubTator, text miningPubMed
Microcavitary Alginate Hydrogel Reverses Chondrocyte Dedifferentiation via Temporal Modulation of the p53 Pathway.Ann Biomed Eng202642098489PubTator, text miningPubMed
Roles of RRM2 and RRM2B in pyrimidine stress responses and differentiation of acute myeloid leukemia cells.Cell Death Discov202642031709PubTator, text miningPubMed
Adaptive Regulation of dNTP Homeostasis Confers Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.Cancer Res202641941751PubTator, text miningPubMed
Huntingtin (HTT) interactome in regulation of DNA repair/remodeling and RNA processing pathways.Life Sci Alliance202641850723PubTator, text miningPubMed
A Novel Truncating Pathogenic Variant in RRM2B in a Kurdish Family With Autosomal-Dominant Chronic Progressive External Ophthalmoplegia Plus (PEOA5).J Clin Neuromuscul Dis202641766080PubTator, text miningPubMed
Effect of a standardized meal on inflammatory biomarkers.Scand J Clin Lab Invest202641689559PubTator, text miningPubMed

1 to 10 of 1,270

See all 1,270 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/50484

GET https://conductscience.org/api/genes/v1/50484/patents?page=2